Table 1.
Meta-analysis of five validated SNPs using two published melanoma GWAS datasets
| SNP | Gene | Position | Allelea | MDACC (n=858)b | Harvard (n=494)c | Meta-analysis | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
||||||||||||
| EAF | HR (95%CI) | P | FPRP | EAF | HR (95%CI) | P | P-het | I2 | HR (95%CI) | P | ||||
| rs7555155d | RHOU | 1q42.13 | C/T | 0.49 | 0.59 (0.44–0.80) | 0.001 | 0.024 | 0.50 | 0.65 (0.44–0.98) | 0.039 | 0.700 | 0 | 0.61 (0.48–0.78) | 6.63E-05 |
| rs10916352e | RHOU | 1q42.13 | G/C | 0.50 | 1.48 (1.11–1.98) | 0.008 | 0.118 | 0.50 | 1.51 (1.01–2.25) | 0.046 | 0.949 | 0 | 1.49 (1.18–1.88) | 9.04E-04 |
| rs3851552d | ARHGAP22 | 10q11.22 | T/C | 0.35 | 1.45 (1.08–1.96) | 0.015 | 0.184 | 0.36 | 1.61 (1.07–2.43) | 0.024 | 0.691 | 0 | 1.50 (1.18–1.91) | 9.58E-04 |
| rs72635537e | ARHGAP44 | 17p12 | C/T | 0.08 | 1.99 (1.28–3.11) | 0.002 | 0.170 | 0.11 | 1.90 (1.12–3.24) | 0.018 | 0.897 | 0 | 1.96 (1.39–2.75) | 1.21E-04 |
| rs7826362e | ARHGEF10 | 8p23.3 | C/T | 0.31 | 1.48 (1.08–2.03) | 0.015 | 0.196 | 0.29 | 1.58 (1.07–2.35) | 0.022 | 0.790 | 0 | 1.52 (1.19–1.94) | 8.47E-04 |
Abbreviations: SNP, single nucleotide polymorphism; GWAS, genome-wide association study; MDACC, The University of Texas M.D. Anderson Cancer Center; EAF, effect allele frequency; HR, hazards ratio; FPRP, false positive report probability; CI, confidence interval; Phet, P value for heterogeneity by Cochrane’s Q test.
a
Reference allele/effect allele.
b
Adjusted for age, sex, Breslow thickness, stage, ulceration, and mitotic rate in the additive model.
c
Adjusted for age and sex in the additive model.
d
Genotyped SNP in the MDACC study.
e
Imputed SNP in the MDACC study.